In an unprecedented move, the FDA today granted accelerated approval to the cancer drug pembrolizumab (Keytruda – Merck & Co) for treatment of any unresectable or metastatic solid tumors associated with the genetic abnormality known as microsatellite instability. It’s the first time the agency approved a cancer treatment or indication that is not for a tumor
